The most specific finding is tender or thickened temporal arteries with decreased ... or rarely over the orbits. Giant cell arteritis is a systemic vasculitis and careful attention should be ...

Based Performance of Inflammatory Markers in Giant Cell Arteritis,” published in the March 2025 issue of American Journal of ...

Are you waking up in the morning with stiff hips, back and neck? You might want to get yourself checked for Polymyalgia Rheumatica (PMR). PMR is a condition characterized by inflammation that leads to ...

Giant cell arteritis, or GCA, is a condition where arteries in the head and neck become inflamed. It is called ‘giant cell’ because abnormally large cells accumulate in the artery walls.

Use of upadacitinib in GCA is not currently approved in the EU. Giant cell arteritis (GCA), also known as temporal arteritis, is an autoimmune disease of medium and large arteries, characterized by ...

The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA) 1 The primary ...

AbbVie immunology clinical development global head and vice-president Kori Wallace stated: "The CHMP's positive opinion for upadacitinib for adults living with giant cell arteritis is an important ...

Find effective medications for 'Temporal Arteritis treatment right here!' This page is a trusted source for both professionals and patients, detailing brand-name and generic options designed to ...

Giant cell arteritis (GCA ... It has been alternatively called cranial arteritis or temporal arteritis, reflecting the most commonly affected vessels. However, this terminology minimizes the ...

temporal arteritis, also known as giant cell arteritis, may occur in up to 20% of people with PMR. Rapid onset of new or frequent headaches (with or without scalp sensitivity or pain), jaw or ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq) to treat adults with giant cell arteritis (GCA).